These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 35428026)

  • 1. A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients.
    Chen Y; Zheng X; Lin J; Gao X; Xiong J; Liu J; Fei Z; Chen C
    Oral Oncol; 2022 May; 128():105860. PubMed ID: 35428026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types.
    Budczies J; Kluck K; Beck S; Ourailidis I; Allgäuer M; Menzel M; Kazdal D; Perkhofer L; Kleger A; Schirmacher P; Seufferlein T; Stenzinger A
    J Pathol Clin Res; 2022 Jul; 8(4):371-382. PubMed ID: 35384413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homologous recombination deficiency (HRD) is associated with better prognosis and possibly causes a non-inflamed tumour microenvironment in nasopharyngeal carcinoma.
    Zhou X; Ying H; Sun Y; Zhang W; Luo P; Zhu S; Zhang J
    J Pathol Clin Res; 2024 Sep; 10(5):e12391. PubMed ID: 39104056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-cancer analysis reveals homologous recombination deficiency score as a predictive marker for immunotherapy responders.
    Yang C; Zhang Z; Tang X; Zhang X; Chen Y; Hu T; Zhang H; Guan M; Zhang X; Wu Z
    Hum Cell; 2022 Jan; 35(1):199-213. PubMed ID: 34628623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
    Miller RE; Leary A; Scott CL; Serra V; Lord CJ; Bowtell D; Chang DK; Garsed DW; Jonkers J; Ledermann JA; Nik-Zainal S; Ray-Coquard I; Shah SP; Matias-Guiu X; Swisher EM; Yates LR
    Ann Oncol; 2020 Dec; 31(12):1606-1622. PubMed ID: 33004253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.
    Wang J; Sun H; Zeng Q; Guo XJ; Wang H; Liu HH; Dong ZY
    Sci Rep; 2019 Sep; 9(1):13404. PubMed ID: 31527697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
    Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
    Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep Learning Artificial Intelligence Predicts Homologous Recombination Deficiency and Platinum Response From Histologic Slides.
    Bergstrom EN; Abbasi A; Díaz-Gay M; Galland L; Ladoire S; Lippman SM; Alexandrov LB
    J Clin Oncol; 2024 Oct; 42(30):3550-3560. PubMed ID: 39083703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
    Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
    Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
    [No Abstract]   [Full Text] [Related]  

  • 10. FAT1 as a tumor mutation burden specific gene affects the immunotherapy effect in head and neck squamous cell cancer.
    Cao H; Lan T; Kuang S; Wang L; Li J; Li Q; Li Y; Xu Q; Chen Q; Ren S; Lan C; Ouyang N; Liao J; Huang Y; Li J
    Drug Resist Updat; 2024 Sep; 76():101095. PubMed ID: 38986165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data.
    Moutafi M; Economopoulou P; Rimm D; Psyrri A
    Oral Oncol; 2021 Jun; 117():105292. PubMed ID: 33862558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homologous recombination deficiency status predicts response to immunotherapy-based treatment in non-small cell lung cancer patients.
    Gao A; Wang X; Wang J; Zhong D; Zhang L
    Thorac Cancer; 2024 Sep; 15(25):1842-1853. PubMed ID: 39081050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications.
    Moretto R; Elliott A; Zhang J; Arai H; Germani MM; Conca V; Xiu J; Stafford P; Oberley M; Abraham J; Spetzler D; Rossini D; Antoniotti C; Marshall J; Shields A; Lopes G; Lonardi S; Pietrantonio F; Tomasello G; Passardi A; Tamburini E; Santini D; Aprile G; Masi G; Falcone A; Lenz HJ; Korn M; Cremolini C
    J Natl Cancer Inst; 2022 Feb; 114(2):271-279. PubMed ID: 34469533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma.
    Xu X; Li R; Zhang L; Zhu G; Ren D; Wu L; Gong X
    Diagn Pathol; 2021 Nov; 16(1):110. PubMed ID: 34823553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer.
    How JA; Jazaeri AA; Fellman B; Daniels MS; Penn S; Solimeno C; Yuan Y; Schmeler K; Lanchbury JS; Timms K; Lu KH; Yates MS
    Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors.
    Paulet L; Trecourt A; Leary A; Peron J; Descotes F; Devouassoux-Shisheboran M; Leroy K; You B; Lopez J
    Eur J Cancer; 2022 May; 166():87-99. PubMed ID: 35279473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor mutational burden predictability in head and neck squamous cell carcinoma patients treated with immunotherapy: systematic review and meta-analysis.
    Rodrigo JP; Sánchez-Canteli M; Otero-Rosales M; Martínez-Camblor P; Hermida-Prado F; García-Pedrero JM
    J Transl Med; 2024 Feb; 22(1):135. PubMed ID: 38311741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Assessment of Diagnostic Homologous Recombination Deficiency-Associated Mutational Signatures in Ovarian Cancer.
    Sztupinszki Z; Diossy M; Borcsok J; Prosz A; Cornelius N; Kjeldsen MK; Mirza MR; Szallasi Z
    Clin Cancer Res; 2021 Oct; 27(20):5681-5687. PubMed ID: 34380641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of HRD functional phenotype impedes immunotherapy and can be reversed by HDAC inhibitor in ovarian cancer.
    Yang D; Huang FX; Wei W; Li QQ; Wu JW; Huang Y; Li ZL; Zhang HL; Li X; Yuan QE; Chen QS; Feng GK; Rong D; Li JD; Zhu XF
    Int J Biol Sci; 2023; 19(6):1846-1860. PubMed ID: 37063431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer.
    Heitmann J; Geeleher P; Zuo Z; Weichselbaum RR; Vokes EE; Fetscher S; Seiwert TY
    Oral Oncol; 2014 Sep; 50(9):825-31. PubMed ID: 25017803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.